-Reuters
AZZ Reports Mixed Q3 Results, Narrows FY22 EPS Outlook
AZZ Inc (NYSE:AZZ) reported third-quarter FY22 sales growth of 2.3% year-over-year to $231.74 million, missing the consensus of $238.63 million. EPS…
Related Posts
YouTube To Delete Videos On Vaccine Misinformation
Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) YouTube will delete any content questioning any approved medical vaccine, the company blogged. The ban extends…
CureVac Announces It’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
CureVac N.V. (NASDAQ:CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the independent
Criteo Q2 EPS $0.58 Beats $0.43 Estimate, Revenue $495M
Criteo (NASDAQ:CRTO) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.43 by 34.88 percent. This is a 7.94 percent decrease over earnings of $0.63 per share from the same